Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus (EDITION IV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01683266|
Recruitment Status : Completed
First Posted : September 11, 2012
Results First Posted : April 23, 2015
Last Update Posted : June 24, 2015
- To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants with type 1 diabetes mellitus
- To compare HOE901-U300 and Lantus when given in the morning or in the evening in terms of:
- Change of HbA1c from baseline to endpoint (scheduled Month 6)
- Change from baseline to endpoint (Month 6) in fasting plasma glucose (FPG), plasma glucose prior to injection of study drug, plasma glucose at 03:00 hours, mean plasma glucose (8-point profiles), glucose variability, treatment satisfaction and health related quality of life in participants with Type 1 Diabetes Mellitus (T1DM)
- Reaching target HbA1c values and controlled plasma glucose (all and reaching target without hypoglycemia)
- Frequency of occurrence and diurnal distribution of hypoglycemia by category of hypoglycemia (symptomatic, asymptomatic, nocturnal, severe, probable and relative)
- Safety and tolerability of HOE901-U300 including development of anti-insulin antibody (AIAs) during the 12-month study period
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes Mellitus||Drug: HOE901-U300 (Insulin glargine new formulation) Drug: Lantus (Insulin glargine)||Phase 3|
The maximum study duration was up to approximately 54 weeks per participants:
- Up to 2-week screening period
- 6-month open-label comparative efficacy and safety treatment period
- 6-month open-label comparative safety extension period
- 48-hour post-treatment safety follow-up period
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||549 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period|
|Study Start Date :||September 2012|
|Actual Primary Completion Date :||September 2013|
|Actual Study Completion Date :||March 2014|
HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
Drug: HOE901-U300 (Insulin glargine new formulation)
Active Comparator: Lantus
Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Drug: Lantus (Insulin glargine)
- Change In HbA1c From Baseline to Month 6 Endpoint [ Time Frame: Baseline, Month 6 ]
- Percentage of Participants With HbA1c <7% at Month 6 Endpoint [ Time Frame: Month 6 ]
- Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint [ Time Frame: Month 6 ]
- Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint [ Time Frame: Baseline, Month 6 ]Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.
- Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint [ Time Frame: Baseline, Month 6 ]Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.
- Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint [ Time Frame: Baseline, Month 6 ]
- Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6 [ Time Frame: Month 6 ]
- Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint [ Time Frame: Month 6 ]
- Change in 8--Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint [ Time Frame: Baseline, Month 6 ]Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.
- Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint [ Time Frame: Baseline, Month 6 ]
- Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint [ Time Frame: Baseline, Month 6 ]DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.
- Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12 [ Time Frame: Up to Month 12 ]Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of <=3.9 mmol/L [70 mg/dL]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level <=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level <=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level >3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose <=3.9 mmol/L).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01683266
Show 147 Study Locations
|Study Director:||Clinical Sciences & Operations||Sanofi|